This site is intended for US healthcare professionals only.

Important Safety Information and Indications

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.

CMS approves Transitional Pass-Through Status and New Billing Code. Click here to learn more.

For the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement

Staying
Power

OTIPRIO® is the first and only single-dose ciprofloxacin otic suspension
Thermosensitive liquid-to-gel technology

See how OTIPRIO works - Watch the method of action video and learn about the proprietary technology of OTIPRIO

OTIPRIO preparation video - See how OTIPRIO is prepared for administration by watching the 
instructional video

REIMBURSEMENT - Learn more about the transitional-pass through status for OTIPRIO and new billing code

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.

WARNINGS AND PRECAUTIONS

Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.

ADVERSE REACTIONS

Adverse reactions (incidence at least 3%) that occurred in two Phase 3 trials with OTIPRIO vs sham were: nasopharyngitis (5% vs 4%), irritability (5% vs 3%), and rhinorrhea (3% vs 2%).

USE IN SPECIFIC POPULATIONS

Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.

Indications and Usage

OTIPRIO® (ciprofloxacin otic suspension) 6% is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.

Please see full Prescribing Information.